Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Med ; 137(6): 490-493, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38490308

ABSTRACT

On January 18, 2024, the US Centers for Disease Control and Prevention issued their most recent guidelines for over-the-counter drugs for coronavirus disease 2019 (COVID-19). Specifically, the organization stated that "Most people with COVID-19 have mild illness and can recover at home. You can treat symptoms with over-the-counter medicines, such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil), to help you feel better." In this review we consider the contributions of different types of evidence and conclude that healthcare providers should make individual clinical judgments for each of their patients in the selection of over-the-counter drugs to treat symptoms of COVID-19. This judgment should be based on the entire benefit to risk profile of the patient. It is our belief that the individual healthcare provider knows far more about each of his or her patients than anyone, including expert members of guideline committees. Their astute and judicious individual clinical decision-making for each individual patient based on all these considerations has the potential to do far more good than harm.


Subject(s)
COVID-19 Drug Treatment , Nonprescription Drugs , Practice Guidelines as Topic , Humans , Nonprescription Drugs/therapeutic use , COVID-19 , United States , SARS-CoV-2 , Health Personnel , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...